

Cancer in the European community and its member sta

European Journal of Cancer & Clinical Oncology
26, 1167-1256

DOI: 10.1016/0277-5379(90)90278-2

Citation Report

#	ARTICLE	IF	CITATIONS
1	Undertreatment of cancer pain. Lancet, The, 1991, 337, 1294.	13.7	8
2	Cancer incidence registration. European Journal of Cancer & Clinical Oncology, 1991, 27, 112-113.	0.7	1
3	Report on consensus meeting of the EORTC melanoma group of educational needs for primary and secondary prevention of melanoma in Europe. European Journal of Cancer & Clinical Oncology, 1991, 27, 1317-1323.	0.7	22
4	Hodgkin's disease mortality in Europe. British Journal of Cancer, 1991, 64, 723-734.	6.4	14
5	Treatment of cancer in the elderly. British Journal of Cancer, 1991, 64, 993-995.	6.4	30
6	Cancer mortality in the ussr, 1986-88. International Journal of Cancer, 1991, 49, 678-683.	5.1	6
7	Tumour Markers in Prostatic Cancer. Scandinavian Journal of Clinical and Laboratory Investigation, 1991, 51, 42-51.	1.2	5
8	Epidemiology on Malignant Melanoma in Europe. Acta OncolÃ³gica, 1992, 31, 903-908.	1.8	71
10	Chemotherapy in Head and Neck Cancer (I): Management of Recurrent or Metastatic Disease. Journal of Chemotherapy, 1992, 4, 244-259.	1.5	4
11	Improving communications in clinical oncology: the EuroCODE project. British Journal of Cancer, 1992, 66, 607-609.	6.4	4
12	The epidemiology of AIDS-associated non-Hodgkin's lymphoma in the World Health Organization European Region. British Journal of Cancer, 1992, 66, 912-916.	6.4	57
13	Special article: The epidemiology of acquired immunodeficiency syndrome and associated tumours in Europe. Annals of Oncology, 1992, 3, 595-603.	1.2	36
14	Treatment of advanced ovarian cancer: 10 years of experience. Annals of Oncology, 1992, 3, 17-27.	1.2	19
15	Clinical breast cancer, new developments in selection and endocrine treatment of patients. Journal of Steroid Biochemistry and Molecular Biology, 1992, 43, 211-221.	2.5	42
16	Trends in cancer mortality in Europe. European Journal of Cancer, 1992, 28, 7-8.	2.8	5
17	Cancer incidence in the province of Limburg, The Netherlands. European Journal of Cancer, 1992, 28, 1752-1755.	2.8	12
18	Trends of cancer mortality in europe, 1955â€“1989: I, digestive sites. European Journal of Cancer, 1992, 28, 132-235.	2.8	133
19	Descriptive epidemiology of ovarian cancer in Europe. Gynecologic Oncology, 1992, 46, 208-215.	1.4	28

#	ARTICLE	IF	CITATIONS
20	The measurement of photodamage. British Journal of Dermatology, 1992, 127, 7-13.	1.5	41
21	Oesophageal cancer mortality in Europe: paradoxical time trend in relation to smoking and drinking. British Journal of Cancer, 1992, 65, 613-617.	6.4	15
22	Increases in mortality from cutaneous melanoma in Southern Europe. International Journal of Cancer, 1992, 51, 160-162.	5.1	17
23	Prostate cancer. Primary hormonal treatment. Cancer, 1993, 71, 1050-1058.	4.1	44
24	Systematic overview (metaanalysis) of all randomized trials of treatment of prostate cancer. Cancer, 1993, 72, 3847-3850.	4.1	14
25	Overexpression of p53 and prognosis in breast cancer. Cancer, 1993, 72, 3641-3647.	4.1	195
26	Estimates of the worldwide incidence of eighteen major cancers in 1985. International Journal of Cancer, 1993, 54, 594-606.	5.1	1,483
27	Cancer in the elderly. Current Problems in Cancer, 1993, 17, 149-218.	2.0	15
28	Overview of the current status of total androgen deprivation in metastasized prostate cancer. World Journal of Urology, 1993, 11, 233-6.	2.2	2
29	Colorectal cancer in Denmark 1943-1988. International Journal of Colorectal Disease, 1993, 8, 42-47.	2.2	19
30	Cancer Etiology: Agents Causally Associated with Human Cancer. Basic and Clinical Pharmacology and Toxicology, 1993, 72, 4-11.	0.0	14
31	Occurrence of Carcinogens in the External Environment: Epidemiological Investigations. Basic and Clinical Pharmacology and Toxicology, 1993, 72, 39-45.	0.0	3
32	Trends in mortality from malignant cutaneous melanoma in The Netherlands, 1950-1988. European Journal of Cancer, 1993, 29, 107-111.	2.8	26
33	The incidence of colon, breast and prostate cancer in Italian migrants to Victoria, Australia. European Journal of Cancer, 1993, 29, 1735-1740.	2.8	10
34	Childhood cancer mortality in the European Community, 1950-1989. European Journal of Cancer, 1993, 29, 1783-1789.	2.8	17
35	Cancer incidence in the Commonwealth of Independent States, the Baltic States and Georgia-The former U.S.S.R.. European Journal of Cancer, 1993, 29, 1609-1620.	2.8	5
36	Screening for prostate cancer-Necessity or nonsense?. European Journal of Cancer, 1993, 29, 656-661.	2.8	51
37	Prognosis of rectal cancer in France. European Journal of Cancer, 1993, 29, 263-266.	2.8	5

#	ARTICLE	IF	CITATIONS
38	How cost-effective is breast cancer screening in different EC countries?. European Journal of Cancer, 1993, 29, 1663-1668.	2.8	55
39	Risk of preneoplastic and neoplastic events in operated oral leukoplakias. European Journal of Cancer Part B, Oral Oncology, 1993, 29, 23-28.	0.9	54
40	Opiophobia and cancer pain. Lancet, The, 1993, 341, 1473-1475.	13.7	15
41	HDR versus LDR gynecological brachytherapy revisited. Radiotherapy and Oncology, 1993, 28, 118-126.	0.6	34
42	Modalities available for screening for prostate cancer. European Journal of Cancer, 1993, 29, 804-811.	2.8	33
43	Risk factors for prostate and testicular cancer. European Journal of Cancer, 1993, 29, 1048-1055.	2.8	45
44	Oral cancer: necessity for prevention strategies. Lancet, The, 1993, 342, 1129.	13.7	34
45	Growth Factors.. Annals of the New York Academy of Sciences, 1993, 698, 85-101.	3.8	9
46	Protective Mechanisms of Dietary Fibers in Nutritional Carcinogenesis. , 1993, 61, 45-63.		35
47	Vegetarians and Longevity. Epidemiology, 1993, 4, 278.	2.7	2
48	Prostate cancer: to screen or not to screen?. BMJ: British Medical Journal, 1993, 306, 407-408.	2.3	80
49	Screening for prostatic cancer: Author's reply. BMJ: British Medical Journal, 1993, 306, 856-856.	2.3	0
50	Screening for prostatic cancer. BMJ: British Medical Journal, 1993, 306, 856-856.	2.3	0
51	Routine follow-up of patients after primary therapy for early breast cancer: Changing concepts and challenges for the future. Annals of Oncology, 1993, 4, 199-204.	1.2	39
52	Screening for prostatic cancer.. BMJ: British Medical Journal, 1993, 306, 855-856.	2.3	0
53	Screening for prostatic cancer.. BMJ: British Medical Journal, 1993, 306, 856-856.	2.3	0
54	Mortality from Skin Melanoma in Italy and Friuli-Venezia Giulia Region, 1970-1989. Tumori, 1994, 80, 251-256.	1.1	9
55	Quality Assessment of Tumor Marker Determinations: A Proposal for a Supraregional Scheme. International Journal of Biological Markers, 1994, 9, 48-52.	1.8	0

#	ARTICLE	IF	CITATIONS
56	Dietary habits and colorectal cancer in a low-risk area. Results from a population-based case-control study in southern Italy. <i>Nutrition and Cancer</i> , 1994, 21, 233-246.	2.0	80
57	Rising trends of oral cancer mortality among males worldwide: the return of an old public health problem. <i>Cancer Causes and Control</i> , 1994, 5, 259-265.	1.8	134
58	Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetate [1]. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1994, 21, 1366-1366.	2.1	0
59	The value of prognostic factors in prostatic cancer. <i>International Urology and Nephrology</i> , 1994, 26, 541-547.	1.4	4
60	Production and response of human prostate cancer cell lines to granulocyte macrophage-colony stimulating factor. <i>International Journal of Cancer</i> , 1994, 59, 235-241.	5.1	44
61	Screening for carcinoma of the prostate: a GP based study. <i>British Journal of Urology</i> , 1994, 74, 64-71.	0.1	27
62	Non-Hodgkin's lymphoma after kidney or heart transplantation: frequency of occurrence during the first posttransplant year. <i>Transplant International</i> , 1994, 7, 353-356.	1.6	18
63	Health issues for Europe. <i>Lancet, The</i> , 1994, 343, 245-246.	13.7	2
64	Cervical cancer screening. Human benefits and human costs in the evaluation of screening programmes. <i>European Journal of Cancer</i> , 1994, 30, 873-875.	2.8	15
65	Breast cancer screening: Methods, human benefits, human costs. <i>European Journal of Cancer</i> , 1994, 30, 875-877.	2.8	0
66	Detection of lymph node metastases in lung cancer: comparison of 131I-Anti-CEA-Anti-CA 19-9 immunoscintigraphy versus computed tomography. <i>Lung Cancer</i> , 1994, 11, 209-219.	2.0	11
67	Estimating the incidence of cancers in Switzerland: 1983-1987. <i>European Journal of Cancer</i> , 1994, 30, 978-982.	2.8	3
68	The Aged Patient with Lung Cancer. <i>Drugs and Aging</i> , 1994, 4, 34-46.	2.7	14
69	Clinical and Economic Considerations in the Treatment of Prostate Cancer. <i>Pharmacoeconomics</i> , 1994, 6, 127-141.	3.3	11
70	What treatment for elderly patients with aggressive lymphoma?. <i>Annals of Oncology</i> , 1994, 5, 873-875.	1.2	35
71	Bioconversion of Prodrugs by Conjugate-Processing Enzymes. <i>Advances in Pharmacology</i> , 1994, 27, 479-499.	2.0	2
72	THE VALUE OF NEOADJUVANT THERAPY IN LOCALIZED PROSTATE CANCER. <i>International Journal of Urology</i> , 1995, 2, 1-5.	1.0	4
73	The value of prostatic specific antigen in the early diagnosis of prostatic cancer: a Greek view. <i>British Journal of Urology</i> , 1995, 75, 637-641.	0.1	5

#	ARTICLE	IF	CITATIONS
74	Prognostic value of prostate-specific antigen minimum after orchidectomy in patients with stage C and D prostatic carcinoma. British Journal of Urology, 1995, 76, 34-40.	0.1	0
75	Evaluation of patients with diseases of the prostate using prostate-specific antigen density. British Journal of Urology, 1995, 76, 41-46.	0.1	0
76	Prognostic value of prostate-specific antigen minimum after orchidectomy in patients with stage C and D prostatic carcinoma. British Journal of Urology, 1995, 76, 34-40.	0.1	4
77	Evaluation of patients with diseases of the prostate using prostate-specific antigen density. British Journal of Urology, 1995, 76, 41-46.	0.1	10
78	Patterns of cigarette sales and lung cancer mortality in some central and eastern European countries, 1960-1989. Cancer, 1995, 75, 2452-2460.	4.1	30
79	Comparisons of colon cancer survival among european countries: The eurocare study. International Journal of Cancer, 1995, 63, 43-48.	5.1	64
80	Treatment of advanced epithelial ovarian cancer: past, present and future. Critical Reviews in Oncology/Hematology, 1995, 20, 41-59.	4.4	6
81	Use of an optical biosensor to measure prostate-specific antigen in whole blood. Sensors and Actuators B: Chemical, 1995, 29, 79-83.	7.8	12
82	Il follow-up longitudinale del paziente sottoposto a screening per carcinoma prostatico: Follow-up of patients submitted to screening for prostate cancer. Urologia, 1995, 62, 83-88.	0.7	0
83	Comparing Two Modalities of Screening for Prostate Cancer: Digital Rectal Examination + Transrectal Ultrasonography Vs. Prostate-Specific Antigen. Tumori, 1995, 81, 225-229.	1.1	22
84	Prostate Cancer: Population-Based Survival Rates in Central Italy. Tumori, 1995, 81, 81-85.	1.1	3
85	Bionutrition and Oral Cancer in Humans. Critical Reviews in Oral Biology and Medicine, 1995, 6, 5-17.	4.4	62
86	Patterns of gastric cancer care by age. A registry-based study in Romagna, Italy. European Journal of Cancer, 1995, 31, 1548-1549.	2.8	2
87	European School of Oncology Advisory report to the European Commission for the "Europe Against Cancer Programme"-European Code Against Cancer. European Journal of Cancer, 1995, 31, 1395-1405.	2.8	77
88	Increasing incidence of cancer of the sigmoid and ascending colon for men in South-east Netherlands. European Journal of Cancer, 1995, 31, 2116-2117.	2.8	4
89	â€Tomudexâ€™ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. European Journal of Cancer, 1995, 31, 1945-1954.	2.8	125
90	European school of oncology advisory report to the European Commission for the Europe against cancer programme: Oral carcinogenesis in Europe. European Journal of Cancer Part B, Oral Oncology, 1995, 31, 75-85.	0.9	45
91	Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology, 1995, 46, 47-55.	1.0	79

#	ARTICLE	IF	CITATIONS
92	Prostate cancer screening and prevention: â€œrealities and hopeâ€. Urology, 1995, 46, 56-61.	1.0	13
93	Screening, early detection, and treatment of prostate cancer: A European view. Urology, 1995, 46, 62-70.	1.0	56
94	Time-trend analysis of mortality from malignant tumors of the nervous system in Spain, 1952â€“1986. Journal of the Neurological Sciences, 1995, 131, 15-20.	0.6	8
95	Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. European Journal of Surgical Oncology, 1995, 21, 517-522.	1.0	220
96	Immunohistochemical expression of p53 protein and proliferating cell nuclear antigen in hepatocellular carcinoma. Pathology Research and Practice, 1995, 191, 1208-1213.	2.3	14
97	Original Articles: Bladder Cancer: The Risk of Urethral Tumors in Female Bladder Cancer: Can the Urethra be Used for Orthotopic Reconstruction of the Lower Urinary Tract?. Journal of Urology, 1995, 153, 950-955.	0.4	141
99	Significance of Serum Free Prostate Specific Antigen in the Screening of Prostate Cancer. Journal of Urology, 1996, 156, 1964-1968.	0.4	37
100	Metabolic Imaging of Untreated Prostate Cancer by Positron Emission Tomography with sup 18 Fluorine-Labeled Deoxyglucose. Journal of Urology, 1996, 155, 994-998.	0.4	279
101	Combined androgen blockade for the treatment of metastatic cancer of the prostate. Urology, 1996, 47, 622-628.	1.0	32
102	Breast Cancer Incidence in Palermo City (Italy). Annals of the New York Academy of Sciences, 1996, 784, 467-471.	3.8	5
103	CYP2D6 genotypes in Spanish women with breast cancer. Cancer Letters, 1996, 99, 23-28.	7.2	24
104	Update on urologyâ€™ prostate cancer. European Journal of Surgical Oncology, 1996, 22, 189-191.	1.0	0
105	A Combined Analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council Randomized Clinical Trials for the Prophylactic Treatment of Stage TaT1 Bladder Cancer. Journal of Urology, 1996, 156, 1934-1941.	0.4	260
106	Is Serum PSA Measurement a Good Test for Early Diagnosis of Prostate Cancer? Results of a Pilot Study and Cost Analysis. International Journal of Biological Markers, 1996, 11, 18-23.	1.8	1
107	Attitudes of Non-Oncology Physicians Dealing with Cancer Patients. A Survey Based on Clinical Scenarios in Ancona Province, Central Italy. Tumori, 1996, 82, 423-429.	1.1	9
108	Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS.. American Journal of Respiratory and Critical Care Medicine, 1996, 154, 725-733.	5.6	68
109	Phase II study of gemcitabine in patients with advanced pancreatic cancer. British Journal of Cancer, 1996, 73, 101-105.	6.4	336
110	Prospects for prostatic cancer incidence and treatment by the year 2000. Journal of Developmental and Physical Disabilities, 1996, 19, 1-10.	3.6	4

#	ARTICLE	IF	CITATIONS
111	Lung cancer mortality among males of Catalonia and Spain compared with other European countries between 1975â€“1977 and 1987â€“1989. , 1996, 65, 751-754.		9
112	Cancer registries in epidemiologic research. Cancer Causes and Control, 1996, 7, 299-301.	1.8	22
113	Nutrition and oral cancer. Cancer Causes and Control, 1996, 7, 101-111.	1.8	79
114	A multicentre phase II study of docetaxel 75 mg m ⁻² as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. British Journal of Cancer, 1996, 74, 650-656.	6.4	83
115	Case-control study of risk factors for prostate cancer. British Journal of Cancer, 1996, 74, 1682-1686.	6.4	75
116	A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Annals of Oncology, 1996, 7, 165-171.	1.2	90
117	Time trend and age-period-cohort effects on gastric cancer incidence in Zaragoza and Navarre, Spain.. Journal of Epidemiology and Community Health, 1997, 51, 412-417.	3.7	15
118	Attitudes and views of physicians and nurses towards cancer patients dying at home. Palliative Medicine, 1997, 11, 116-126.	3.1	21
119	Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. British Journal of Cancer, 1997, 76, 651-657.	6.4	71
120	Bladder Cancer in Estonia, 1968-1992: Incidence, Mortality, Prevalence and Survival. Scandinavian Journal of Urology and Nephrology, 1997, 31, 337-342.	1.4	9
121	Prostate Cancer in Nigerians: Facts and Nonfacts. Journal of Urology, 1997, 157, 1340-1343.	0.4	87
123	Comparison of cutaneous malignant melanoma in two European countries. European Journal of Oncology Nursing, 1997, 1, 208-214.	0.1	0
124	Smoking Behavior in a Swiss Urban Population: The Role of Gender and Education. Preventive Medicine, 1997, 26, 658-663.	3.4	28
125	Gastric cancer in the European Union (1968â€“1992): Mortality trends and cohort effect. Annals of Epidemiology, 1997, 7, 294-303.	1.9	36
126	Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990. European Journal of Cancer, 1997, 33, 1075-1107.	2.8	447
127	Duration of colorectal cancer symptoms and survival: the effect of confounding clinical and pathological variables. European Journal of Cancer, 1997, 33, 1461-1467.	2.8	59
128	Cancer burden in Europe for 1990: Can we predict the figures for the year 2000?. European Journal of Cancer, 1997, 33, 991-996.	2.8	6
129	Cervical cancer mortality in Belgium, 1955â€“1989. A descriptive study. European Journal of Cancer, 1997, 33, 1841-1845.	2.8	14

#	ARTICLE	IF	CITATIONS
130	Ki-ras oncogene and p53 tumour suppressor gene mutations in colorectal carcinomas from the European Saar-Luxembourg region are less frequent than predicted by the classic adenoma-carcinoma sequence model. <i>European Journal of Cancer</i> , 1997, 33, 2265-2272.	2.8	8
131	Surveillance after colorectal cancer surgery. <i>European Journal of Surgical Oncology</i> , 1997, 23, 522-525.	1.0	23
132	Pathological and immunophenotypic features of adult non-Hodgkin's lymphomas by age group. <i>Human Pathology</i> , 1997, 28, 580-587.	2.0	11
133	The Potential Role of Tomudex in the Treatment of Advanced Colorectal Cancer. <i>Tumori</i> , 1997, 83, 576-580.	1.1	4
134	Tobacco smoking. <i>Apmis</i> , 1997, 105, 9-47.	2.0	46
135	Molecular and cellular biology of prostate cancer. <i>Cancer and Metastasis Reviews</i> , 1997, 16, 29-66.	5.9	67
136	Epidemiological characteristics of gastric cancer in Vojvodina. <i>European Journal of Epidemiology</i> , 1997, 13, 523-525.	5.7	6
137	Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. <i>Diseases of the Colon and Rectum</i> , 1997, 40, 1195-1204.	1.3	46
138	Intermittent androgen deprivation in advanced prostate cancer. <i>Urological Research</i> , 1997, 25, S63-S66.	1.5	4
139	Thirty years of medical research council randomized trials in solid tumours. <i>Clinical Oncology</i> , 1997, 9, 100-114.	1.4	54
140	The European randomized study of screening for prostate cancer. <i>Cancer</i> , 1997, 80, 1830-1834.	4.1	37
141	Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study. <i>Investigational New Drugs</i> , 1998, 16, 141-146.	2.6	20
142	Radiological intervention in pancreatic cancer. <i>European Radiology</i> , 1998, 8, 9-15.	4.5	5
143	FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study. <i>British Journal of Cancer</i> , 1998, 77, 1149-1154.	6.4	7
144	Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. <i>British Journal of Cancer</i> , 1998, 78, 1219-1223.	6.4	110
145	Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk. <i>British Journal of Cancer</i> , 1998, 78, 1361-1367.	6.4	53
146	Repair of DNA lesion O 6 -methylguanine in hepatocellular carcinogenesis. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 1998, 5, 355-366.	2.0	15
148	Surgery or radiation: is there really a choice for early prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 1998, 27, 11-27.	4.4	13

#	ARTICLE	IF	CITATIONS
149	Breast cancer. Critical Reviews in Oncology/Hematology, 1998, 27, 135-137.	4.4	5
150	Combined androgen blockade: an optimal therapy for minimally advanced prostate cancer?. BJU International, 1998, 81, 87-95.	2.5	11
151	The value of prostate specific antigen (PSA) density and free: total PSA ratio in selecting patients with a normal digital rectal examination and intermediate total PSA levels for further investigation. British Journal of Urology, 1998, 82, 393-397.	0.1	11
153	Comparison of 5-fluoro-2â€²-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. European Journal of Cancer, 1998, 34, 296-306.	2.8	95
154	Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. Journal of Steroid Biochemistry and Molecular Biology, 1998, 66, 1-10.	2.5	86
155	Photodermatoses. Clinics in Dermatology, 1998, 16, 41-57.	1.6	21
156	Raltitrexed (Tomudex®,). Expert Opinion on Investigational Drugs, 1998, 7, 823-834.	4.1	7
157	Prostate Cancer in Denmark: A 50-Year Population-Based Study. Urology, 1998, 51, 590-594.	1.0	23
159	Screening for Prostate Cancer - More Questions than Answers. Acta OncolÃ³gica, 1998, 37, 515-532.	1.8	9
160	Breast cancer screening programmes in 22 countries: current policies, administration and guidelines. International Breast Cancer Screening Network (IBSN) and the European Network of Pilot Projects for Breast Cancer Screening. International Journal of Epidemiology, 1998, 27, 735-742.	1.9	205
161	Is Prostate-Specific Antigen a Reliable Marker of Bone Metastasis in Patients with Newly Diagnosed Cancer of the Prostate?. European Urology, 1998, 33, 376-381.	1.9	54
162	Multiple Myeloma: Presenting Features and Survival According to Hospital Referral. Leukemia and Lymphoma, 1998, 30, 551-562.	1.3	1
163	Numeric Alterations in Chromosomes 7 and 8 Detected by Fluorescent in situ Hybridization Correlate with High-Grade Localized Prostate Cancer. European Urology, 1998, 34, 419-425.	1.9	11
164	Fortnightly review: Bladder cancer. BMJ: British Medical Journal, 1998, 317, 1366-1369.	2.3	48
165	Screening for prostate cancer. Annals of Oncology, 1998, 9, 1289-1292.	1.2	10
166	The changing landscape of breast cancer clinical research. Annals of Oncology, 1998, 9, 133-138.	1.2	3
167	Chemotherapy for Advanced Pancreatic Cancer: The History is Changing. Tumori, 1998, 84, 308-311.	1.1	5
168	Combined Modality Treatment of Locally Advanced Lung Cancer. Tumori, 1998, 84, 259-269.	1.1	3

#	ARTICLE	IF	CITATIONS
169	Evolution of Isolated High-Grade Prostate Intraepithelial Neoplasia in a Mediterranean Patient Population. <i>European Urology</i> , 1999, 35, 496-497.	1.9	16
170	Chemotherapy for advanced pancreatic cancer: It may no longer be ignored. <i>Annals of Oncology</i> , 1999, 10, 105-110.	1.2	24
171	The Role of Vindesine and Lonidamine in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer: A Phase III Randomized Fonicap Trial. <i>Tumori</i> , 1999, 85, 177-182.	1.1	28
172	The Role of Arterial Embolization in Renal Cell Carcinoma. <i>Scandinavian Journal of Urology and Nephrology</i> , 1999, 33, 162-170.	1.4	106
173	Epidemiology of Prostate Cancer Chemoprevention. <i>European Urology</i> , 1999, 35, 370-376.	1.9	25
174	Trends in mortality from cutaneous malignant melanoma in Belgium. <i>International Journal of Epidemiology</i> , 1999, 28, 40-45.	1.9	8
175	Cancer registry data based estimation of regional cancer incidence: application to breast and colorectal cancer in French administrative regions. <i>Journal of Epidemiology and Community Health</i> , 1999, 53, 558-564.	3.7	31
176	Cost-effectiveness of faecal occult blood screening for colorectal cancer: results of the Nottingham trial. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 32, 155-165.	4.4	11
177	Reirradiation and lomustine in patients with relapsed high-grade gliomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 43, 789-793.	0.8	63
178	Treatment of prostate cancer. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1999, 24, 93-102.	1.5	47
179	Hormonal prevention of breast cancer: proposal for a change in paradigm. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1999, 106, 1006-1018.	2.3	18
180	The plasminogen activation system in lung cancer " with special reference to the prognostic role in "non-small cell lung cancer" Apmis, 1999, 107, 5-29.	2.0	1
181	Weekly epirubicin plus lonidamine in advanced breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 1999, 56, 231-235.	2.5	11
182	H�patocarcinome: ponction-biopsie �choguid�e et traitements percutan�s. <i>Acta Endoscopica</i> , 1999, 29, 483-488.	0.0	0
183	The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma. , 1999, 85, 803-811.		44
184	Dietary fat and carcinogenesis. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 1999, 443, 111-127.	1.7	128
185	Autologous peripheral blood stem cell transplantation for lung cancer. <i>Best Practice and Research in Clinical Haematology</i> , 1999, 12, 233-246.	1.7	4
186	An epidemiological study of lung cancer: history and histological types in a general population in northern Finland. <i>European Respiratory Journal</i> , 1999, 13, 436-440.	6.7	36

#	ARTICLE	IF	CITATIONS
187	Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 3748-3757.	1.6	820
188	Transforming Growth Factor- β 1 and Prostate Cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 2000, 34, 85-94.	1.4	44
189	The performance of SF-36 health survey in patients with laryngeal cancer. , 2000, 22, 175-182.		38
190	Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. , 2000, 42, 18-25.		62
191	National cancer prevalence estimation in France. <i>International Journal of Cancer</i> , 2000, 87, 301-304.	5.1	31
192	Cancer and men from minority ethnic groups: an exploration of the literature. <i>European Journal of Cancer Care</i> , 2000, 9, 221-229.	1.5	9
193	Gemcitabine in locally advanced and/or metastatic bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2000, 34, 175-183.	4.4	14
194	Comparison of human papillomavirus genotypes in archival cervical cancer specimens from Alaska natives, Greenland natives and Danish Caucasians. <i>Microbes and Infection</i> , 2000, 2, 121-126.	1.9	26
195	Weekly schedule of vinorelbine in pretreated breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2000, 59, 223-229.	2.5	21
196	Prostate cancer: to screen or not to screen?. <i>Lancet Oncology</i> , The, 2000, 1, 17-24.	10.7	65
197	Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma. <i>European Journal of Cancer</i> , 2000, 36, 817-820.	2.8	18
198	Unanswered questions in screening for prostate cancer. <i>European Journal of Cancer</i> , 2000, 36, 1316-1321.	2.8	35
199	N-Acetyltransferase 2 (NAT2) Genotype and Colorectal Carcinoma: Risk Variability According to Tumour Site?. <i>Scandinavian Journal of Gastroenterology</i> , 2000, 35, 1087-1091.	1.5	17
200	Epidemiología de los cánceres de las vías aerodigestivas superiores. <i>EMC - Otorrinolaringología</i> , 2000, 29, 1-10.	0.0	0
202	Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. <i>Journal of Hepatology</i> , 2000, 32, 933-939.	3.7	124
203	Prognostic and predictive factors in prostate cancer. <i>Cancer Treatment Reviews</i> , 2001, 27, 143-151.	7.7	26
204	Prognostic significance of factors affecting disease free interval and overall survival for Stage II breast cancer in Greece. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2001, 95, 100-104.	1.1	5
205	Prostate cancer: Natural history and surgical treatment of localised disease. <i>European Journal of Cancer</i> , 2001, 37, 127-136.	2.8	7

#	ARTICLE	IF	CITATIONS
207	The Causes of Dysphagia in Carcinoma of the Lung. Journal of the Royal Society of Medicine, 2001, 94, 567-572.	2.0	32
209	HEALTH TECHNOLOGY ASSESSMENT IN THE AREA OF PREVENTION. International Journal of Technology Assessment in Health Care, 2001, 17, 338-357.	0.5	9
210	The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1758-1765.	6.4	88
211	Influence of the delay of adjuvant postoperative radiation therapy on relapse and survival in oropharyngeal and hypopharyngeal cancers. International Journal of Radiation Oncology Biology Physics, 2001, 49, 139-146.	0.8	59
212	The history, aetiology and epidemiology of laryngeal carcinoma. Clinical Otolaryngology, 2001, 26, 442-446.	0.0	46
213	Expression of p75LNGFR and Trk neurotrophin receptors in normal and neoplastic human prostate. BJU International, 2001, 84, 495-502.	2.5	34
214	Role of transforming growth factor- β 1 in prostate cancer. Microscopy Research and Technique, 2001, 52, 411-419.	2.2	78
215	Overexpression of p16INK4A as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. International Journal of Cancer, 2001, 92, 276-284.	5.1	919
216	Bladder cancer mortality in the Epirus district population (Greece). International Urology and Nephrology, 2001, 32, 377-379.	1.4	2
217	Interactions of human prostatic epithelial cells with bone marrow endothelium: binding and invasion. British Journal of Cancer, 2001, 84, 1417-1423.	6.4	74
218	^{99m} Tc-MIBI scintimammography as a complement of the mammography in patients with suspected breast cancer. A multicentre experience. Breast, 2001, 10, 109-116.	2.2	9
219	Photodynamic therapy for superficial bladder cancer. Expert Review of Anticancer Therapy, 2001, 1, 523-530.	2.4	11
220	Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. British Journal of Cancer, 2002, 87, 497-501.	6.4	22
221	Randomized Comparative Study of Tegafur/Uracil and Oral Leucovorin Versus Parenteral Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2002, 20, 3617-3627.	1.6	254
222	Smoking cessation would substantially reduce the future incidence of pancreatic cancer in the European Union. European Journal of Gastroenterology and Hepatology, 2002, 14, 1343-1353.	1.6	42
223	Positive predictive value of ^{99m} Tc sestamibi scintimammography in patients with non-palpable, mammographically detected, suspicious, breast lesions. Nuclear Medicine Communications, 2002, 23, 1073-1078.	1.1	11
224	Anastrozole in the management of breast cancer. Expert Opinion on Pharmacotherapy, 2002, 3, 1329-1339.	1.8	4
225	Circadian concepts in normal and neoplastic breast. Chronobiology International, 2002, 19, 221-235.	2.0	9

#	ARTICLE	IF	CITATIONS
226	Estimates of cancer incidence and mortality in Europe in 1995. <i>European Journal of Cancer</i> , 2002, 38, 99-166.	2.8	587
227	Incidence of breast cancer on Crete, 1994–1995. <i>European Journal of Cancer</i> , 2002, 38, 574-577.	2.8	10
228	Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk. <i>Cancer Letters</i> , 2002, 180, 41-46.	7.2	23
229	Trend of cervical cancer mortality in Belgium (1954-1994): Tentative solution for the certification problem of unspecified uterine cancer. <i>International Journal of Cancer</i> , 2002, 102, 649-654.	5.1	32
230	N-acetyltransferase 2 single-nucleotide polymorphisms and risk of gastric carcinoma. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 115-118.	1.9	17
231	Change in Anatomic Distribution and Incidence of Colorectal Carcinoma Over a Period of 15 Years. <i>Diseases of the Colon and Rectum</i> , 2002, 45, 1393-1396.	1.3	33
232	Positron emission tomography and colorectal cancer. <i>British Journal of Surgery</i> , 2002, 88, 176-189.	0.3	62
233	Biofeedback vs verbal feedback as learning tools for pelvic muscle exercises in the early management of urinary incontinence after radical prostatectomy. <i>BJU International</i> , 2002, 89, 714-719.	2.5	91
234	Polyphenols in red wine inhibit the proliferation and induce apoptosis of LNCaP cells. <i>BJU International</i> , 2002, 89, 950-954.	2.5	82
235	Residue levels of DDE and PCBs in the blood serum of women in the Port Said region of Egypt. <i>Journal of Hazardous Materials</i> , 2002, 89, 41-48.	12.4	40
236	Hypothesis: does ochratoxin A cause testicular cancer?. <i>Cancer Causes and Control</i> , 2002, 13, 91-100.	1.8	121
237	Prospective Study Comparing Multislice CT Colonography With Colonoscopy in the Detection of Colorectal Cancer and Polyps. <i>Diseases of the Colon and Rectum</i> , 2003, 46, 1384-1390.	1.3	43
238	The Value of Endorectal MRI in the Early Diagnosis of Prostate Cancer. <i>European Urology</i> , 2003, 44, 201-208.	1.9	33
239	Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 47, 127-139.	4.4	36
240	Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). <i>BJU International</i> , 2003, 92, 48-54.	2.5	110
241	Trends in oesophago-gastric surgery in Scotland. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2003, 1, 51-57.	1.8	0
242	Cancer in women. <i>International Journal of Gynecology and Obstetrics</i> , 2003, 82, 369-379.	2.3	84
243	Efficacy of sildenafil in an open-label study as a continuation of a double-blind study in the treatment of erectile dysfunction after radiotherapy for prostate cancer. <i>Urology</i> , 2003, 62, 116-120.	1.0	42

#	ARTICLE	IF	CITATIONS
244	Early diagnosis and surgical management of prostate cancer. <i>Cancer Treatment Reviews</i> , 2003, 29, 151-160.	7.7	23
245	Treatment of operable breast cancer in the elderly. <i>European Journal of Cancer</i> , 2003, 39, 300-308.	2.8	54
246	Treatment of operable breast cancer in the elderly. <i>European Journal of Cancer</i> , 2003, 39, 309-316.	2.8	113
247	Cancer incidence and mortality in Portugal. <i>European Journal of Cancer</i> , 2003, 39, 2507-2520.	2.8	47
248	Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2003, 14, 233-241.	1.2	30
249	Cancer mortality trends in the EU and acceding countries up to 2015. <i>Annals of Oncology</i> , 2003, 14, 1148-1152.	1.2	79
250	Bladder cancer: a current update. <i>British Journal of Hospital Medicine</i> , 2003, 64, 40-42.	0.2	3
251	Can Lifestyle Behaviour Change Reduce the Risk and Incidence of Urological Cancers?. , 0, , 87-100.		0
252	Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. <i>Annals of Oncology</i> , 2004, 15, 467-473.	1.2	84
253	Cancers of the bladder. <i>Perspectives in Public Health</i> , 2004, 124, 228-229.	0.4	39
254	Applicability of biomarkers in the early diagnosis of prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2004, 4, 513-526.	3.1	47
255	Cultures of ovarian surface epithelium from women with and without a hereditary predisposition to develop female adnexal carcinoma. <i>Gynecologic Oncology</i> , 2004, 92, 819-826.	1.4	12
256	Does Positron Emission Tomography Change Management in Primary Rectal Cancer? A Prospective Assessment. <i>Diseases of the Colon and Rectum</i> , 2004, 47, 451-458.	1.3	107
258	Management of small cell lung cancer. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 40-43.	2.2	0
259	Sheep and goats: separating cervix and corpus uteri from imprecisely coded uterine cancer deaths, for studies of geographical and temporal variations in mortality. <i>European Journal of Cancer</i> , 2004, 40, 2794-2803.	2.8	73
261	Gemcitabine Combined With Epirubicin in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 429-435.	1.3	7
262	Comparison of early performance indicators for screening projects within the European Breast Cancer Network: 1989â€“2000. <i>European Journal of Cancer Prevention</i> , 2005, 14, 107-116.	1.3	42
264	A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD). <i>Clinical and Translational Oncology</i> , 2005, 7, 493-498.	2.4	5

#	ARTICLE	IF	CITATIONS
265	Functional and structural imaging of the bladder. <i>Imaging</i> , 2005, 17, 130-138.	0.0	0
266	Screening for Prostate Cancer. , 2005, , 31-40.		0
267	Radiation therapy for prostate cancer and erectile (dys)function: The role of imaging. <i>Acta OncolÃ³gica</i> , 2005, 44, 673-678.	1.8	16
268	Study of Cyfra 21â€“1, a Tumor Marker, in Head and Neck Squamous Cell Carcinoma. <i>Annals of Otology, Rhinology and Laryngology</i> , 2005, 114, 768-776.	1.1	21
269	Epidemiology of Oral Cavity Cancer in Taiwan with Emphasis on the Role of Betel Nut Chewing. <i>Orl</i> , 2005, 67, 230-236.	1.1	64
270	Conservative bladder management in advanced multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 694-699.	3.0	24
271	The curative role of radiotherapy in adenocarcinoma of the prostate in patients under 55 years of age: A rare cancer network retrospective study. <i>Radiotherapy and Oncology</i> , 2005, 77, 286-289.	0.6	19
274	L1 on ovarian carcinoma cells is a binding partner for Neuropilin-1 on mesothelial cells. <i>Cancer Letters</i> , 2006, 239, 212-226.	7.2	44
275	Estimating regional cancer burden in countries with partial registration coverage: An application to all malignant neoplasms in Italy over the period 1970â€“2010. <i>European Journal of Cancer</i> , 2006, 42, 3236-3245.	2.8	19
276	Erectile dysfunction andÂradiation therapy forÂprostate cancer. <i>Sexologies</i> , 2006, 15, 116-120.	0.8	5
277	The effect of performing corrections on reported uterine cancer mortality data in the city of SÃ£o Paulo. <i>Brazilian Journal of Medical and Biological Research</i> , 2006, 39, 1091-1099.	1.5	12
280	Cancer incidence estimates at the national and district levels in Colombia. <i>Salud Publica De Mexico</i> , 2006, 48, 455-465.	0.4	28
281	Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. <i>Prostate</i> , 2006, 66, 591-603.	2.3	44
282	The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. <i>BJU International</i> , 2006, 97, 634-639.	2.5	68
283	The chromogranin-A (CgA) in prostate cancer. <i>Archives of Gerontology and Geriatrics</i> , 2006, 43, 117-126.	3.0	29
284	A Mathematical Estimation of True Cancer Incidence Using Data from Population-based Cancer Registries. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 150-155.	1.3	17
285	Burden of cervical cancer in Europe: estimates for 2004. <i>Annals of Oncology</i> , 2007, 18, 1708-1715.	1.2	110
286	Tadalafil (Cialis) and Erectile Dysfunction After Radiotherapy for Prostate Cancer: An Open-Label Extension of a Blinded Trial. <i>Urology</i> , 2007, 70, 1190-1193.	1.0	31

#	ARTICLE	IF	CITATIONS
287	Molecular targeted therapies in breast cancer: Where are we now?. International Journal of Biochemistry and Cell Biology, 2007, 39, 1375-1387.	2.8	32
289	Are bone scintigraphy examinations requested in oncologic patients according to established indications?. Revista Española De Medicina Nuclear, 2007, 26, 286-293.	0.3	1
291	Communication with Older Breast Cancer Patients. Breast Journal, 2007, 13, 406-409.	1.0	17
292	Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Research and Treatment, 2007, 105, 319-326.	2.5	369
293	Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clinical and Translational Oncology, 2008, 10, 646-653.	2.4	52
294	The epidemiology of mouth cancer: a review of global incidence. Oral Diseases, 2000, 6, 65-74.	3.0	283
295	“Oral cancer”™The terminology dilemma. Oral Diseases, 2000, 6, 191-193.	3.0	23
296	Imaging of Hematuria. Radiologic Clinics of North America, 2008, 46, 113-132.	1.8	61
297	Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Annals of Oncology, 2008, 19, 1110-1116.	1.2	107
298	What is the future for NSAIDS in preventing breast cancer in older women?. Aging Health, 2008, 4, 207-212.	0.3	0
299	Trends in incidence of digestive cancers in France. European Journal of Cancer Prevention, 2008, 17, 13-17.	1.3	26
301	Diet, Micronutrients, and the Prostate Gland. Nutrition Reviews, 2009, 57, 95-103.	5.8	36
302	Responding to the challenge of cancer in Europe. Australian and New Zealand Journal of Public Health, 2009, 33, 298.	1.8	12
303	Trends of cervical cancer mortality in the member states of the European Union. European Journal of Cancer, 2009, 45, 2640-2648.	2.8	247
305	CCR2-64I is a risk factor for development of bladder cancer. Genetics and Molecular Research, 2010, 9, 685-692.	0.2	32
306	Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 246-251.	7.1	530
307	Imaging of Hematuria. American Journal of Roentgenology, 2010, 195, W263-W267.	2.2	37
308	Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer, 2010, 46, 765-781.	2.8	1,947

#	ARTICLE	IF	CITATIONS
309	Factors influencing loco-regional relapse in older breast cancer patients treated with tumour resection and tamoxifen. <i>European Journal of Surgical Oncology</i> , 2011, 37, 1051-1058.	1.0	10
310	Lkb1 and Pten Synergise to Suppress mTOR-Mediated Tumorigenesis and Epithelial-Mesenchymal Transition in the Mouse Bladder. <i>PLoS ONE</i> , 2011, 6, e16209.	2.5	59
311	Reliability of recording uterine cancer in death certification in France and age-specific proportions of deaths from cervix and corpus uteri. <i>Cancer Epidemiology</i> , 2011, 35, 243-249.	1.9	5
312	Spatial Regulation of RhoA Activity during Pancreatic Cancer Cell Invasion Driven by Mutant p53. <i>Cancer Research</i> , 2011, 71, 747-757.	0.9	127
314	Early rehabilitation after surgery improves functional outcome in inpatients with brain tumours. <i>Journal of Neuro-Oncology</i> , 2012, 107, 537-544.	2.9	112
315	Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 35-47.	2.5	37
316	LKB1 mutations and their correlation with LKB1 and Rheb expression in bladder cancer. <i>Molecular Carcinogenesis</i> , 2013, 52, 660-665.	2.7	11
317	Cognitive rehabilitation for early post-surgery inpatients affected by primary brain tumor: a randomized, controlled trial. <i>Journal of Neuro-Oncology</i> , 2013, 114, 93-100.	2.9	104
318	Cancer burden in China: a Bayesian approach. <i>BMC Cancer</i> , 2013, 13, 458.	2.6	13
319	Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. <i>European Journal of Cancer</i> , 2013, 49, 1374-1403.	2.8	4,448
320	Intravital FLIM-FRET Imaging Reveals Dasatinib-Induced Spatial Control of Src in Pancreatic Cancer. <i>Cancer Research</i> , 2013, 73, 4674-4686.	0.9	111
321	Haematuria: An Imaging Guide. <i>Advances in Urology</i> , 2014, 2014, 1-9.	1.3	13
322	Los efectos de resveratrol y otros polifenoles del vino sobre la proliferaci3n, apoptosis y expresi3n de receptor androg3nico en c3lulas LNCaP. <i>Actas Urol3gicas Espa3olas</i> , 2014, 38, 397-404.	0.7	22
323	Effects of resveratrol and other wine polyphenols on the proliferation, apoptosis and androgen receptor expression in LNCaP cells. <i>Actas Urol3gicas Espa3olas (English Edition)</i> , 2014, 38, 397-404.	0.2	15
324	Estimation of cancer burden in Guangdong Province, China in 2009. <i>Chinese Journal of Cancer</i> , 2015, 34, 594-601.	4.9	13
325	Ki-67 and p53 expression as a predictive marker for early postoperative recurrence in pancreatic head cancer. <i>Annals of Surgical Treatment and Research</i> , 2015, 88, 200.	1.0	25
326	The European Cancer Observatory: A new data resource. <i>European Journal of Cancer</i> , 2015, 51, 1131-1143.	2.8	57
327	Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. <i>International Journal of Cancer</i> , 2015, 136, E359-86.	5.1	23,615

#	ARTICLE	IF	CITATIONS
328	Presence, characteristics and equity of access to breast cancer screening programmes in 27 European countries in 2010 and 2014. Results from an international survey. Preventive Medicine, 2016, 91, 250-263.	3.4	44
329	Diagnostic performance of power doppler and ultrasound contrast agents in early imaging-based diagnosis of organ-confined prostate cancer: Is it possible to spare cores with contrast-guided biopsy?. European Journal of Radiology, 2016, 85, 1778-1785.	2.6	7
330	Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. European Journal of Cancer, 2018, 103, 356-387.	2.8	1,789
331	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. JAMA Oncology, 2019, 5, 1749.	7.1	1,691
332	Heme Oxygenase-1 in Central Nervous System Malignancies. Journal of Clinical Medicine, 2020, 9, 1562.	2.4	23
333	The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. European Journal of Cancer, 2021, 157, 308-347.	2.8	243
334	Prostate cancer. Primary hormonal treatment. Cancer, 1993, 71, 1050-1058.	4.1	28
335	Lokoregionäre und systemische Therapie beim fortgeschrittenen Pankreaskarzinom. , 1998, , 1344-1347.		1
336	Role of Prophylactic Cranial Irradiation: Benefits and Late Effects. Medical Radiology, 1999, , 139-149.	0.1	3
337	Complications of Radical Prostatectomy. Medical Radiology, 1996, , 139-156.	0.1	2
338	Breast Cancer: The Scene in Europe. , 1993, , 3-5.		3
340	Epidemiology of Cancer of the Oral Cavity and Oropharynx. Recent Results in Cancer Research, 1994, 134, 1-8.	1.8	2
341	Nutzen und Grenzen von Mutagenitäts- und Kanzerogenitätsstudien. , 1997, , 3-16.		1
343	Brachytherapy of Prostate Cancer and Sexual Dysfunction. UroOncology, 2003, 2, 107-112.	0.1	4
344	Phase II Study of Oral Doxifluridine in Elderly Patients with Advanced Non-Small-Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1996, 19, 592-594.	1.3	9
345	Anastrozole. American Journal of Clinical Oncology: Cancer Clinical Trials, 1998, 21, 161-166.	1.3	6
346	Toxicity and Activity of Docetaxel in Anthracycline-Pretreated Breast Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2000, 23, 132-139.	1.3	39
347	Original Articles. Journal of Urology, 1995, , 950-955.	0.4	38

#	ARTICLE	IF	CITATIONS
348	Metabolic Imaging of Untreated Prostate Cancer by Positron Emission Tomography with sup 18 Fluorine-Labeled Deoxyglucose. Journal of Urology, 1996, , 994-998.	0.4	8
349	A Combined Analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council Randomized Clinical Trials for the Prophylactic Treatment of Stage TaT1 Bladder Cancer. Journal of Urology, 1996, , 1934-1940.	0.4	9
350	Prostate Cancer in Nigerians. Journal of Urology, 1997, , 1340-1343.	0.4	3
351	Detection of prostate cancer. BMJ: British Medical Journal, 1995, 310, 140-141.	2.3	24
352	Colorectal Cancer Mortality in Relation to Glucose - 6 - Phosphate Dehydrogenase Deficiency and Consanguinity in Sardinia: A Spatial Correlation Analysis. Asian Pacific Journal of Cancer Prevention, 2017, 18, 2403-2407.	1.2	10
353	Original Paper Inflammatory changes in biopsy specimens from patients with suspected prostate cancer. Central European Journal of Urology, 2013, 66, 256-62.	0.3	8
354	Significance of atypical small acinar proliferation and extensive high-grade prostatic intraepithelial neoplasm in clinical practice. Central European Journal of Urology, 2014, 67, 136-41.	0.3	14
355	Early Detection and Treatment of Prostate Cancer: a Road to Patient Benefit?. , 2000, , 163-169.		0
356	Radiochemotherapy in Locally Invasive Non-Metastatic Carcinoma of the Bladder. , 2003, 539, 143-153.		0
357	Picture Quiz: Spinal cord compression. BMJ, The, 2003, 326, 030358.	6.0	0
359	CholangiozellulÄres Karzinom. , 2006, , 4027-4044.		0
360	Magenkarzinom. , 2006, , 3737-3768.		1
361	Melanom. , 2006, , 5081-5120.		0
363	Lycopene and Its Potential Role in Prostate Cancer Prevention. , 2009, , 329-351.		0
364	Nierenzellkarzinom. , 2009, , 331-369.		0
365	Laryngeal Cancer. , 2010, , 499-502.		0
366	Nierenzellkarzinom. , 2014, , 347-397.		0
367	Äsophaguskarzinom. , 1993, , 176-183.		0

#	ARTICLE	IF	CITATIONS
368	Diet and Large Bowel Cancer. Advances in Experimental Medicine and Biology, 1993, 348, 107-118.	1.6	1
369	Magenkarzinom. , 1993, , 184-190.		0
371	Nierenzellkarzinome. , 1994, , 21-50.		0
372	Das Zervixkarzinom. Gegenwärtiger Stand und neue Aspekte der systemischen Therapie. , 1994, , 75-92.		0
373	Remarks on Screening and Early Detection of Prostate Cancer. , 1994, , 13-19.		0
374	Epidemiology of Cancer in Women. Medical Science Symposia Series, 1994, , 51-66.	0.0	0
375	Epidemiologie des Prostatakarzinoms. , 1995, , 11-19.		0
376	Suche nach dem Prostatakarzinom – Verbessert die Kombination von DRE, TRUS und PSA die Effizienz des Screenings?. , 1995, , 199-206.		1
377	Ösophaguskarzinom. , 1995, , 500-511.		0
378	Prognosis and Survival in Prostate Cancer. , 1995, , 214-224.		0
380	Skin Damage due to Ultraviolet Light. , 1996, , 447-460.		0
382	Nierenzellkarzinom. , 1997, , 25-55.		0
383	Epidemiología del cáncer invasor de córvix en el Área sanitaria de Girona durante el período 1980 - 1989. Registro poblacional de cáncer de Girona. Revista Espanola De Salud Publica, 1997, 71, 19-26.	0.3	1
384	Tumoren von Gallenblase und Gallenwegen. , 1997, , 797-809.		1
385	Malignes Melanom. , 1997, , 1415-1460.		0
386	Europäischer Kodex gegen den Krebs. , 1997, , 2015-2029.		1
387	Ösophaguskarzinom. , 1998, , 590-605.		0
388	Magenkarzinom. , 1998, , 606-620.		0

#	ARTICLE	IF	CITATIONS
389	FrÃ¼herkennung/Vorsorge. , 1998, , 105-284.		0
391	Retinoids and Breast Cancer. , 2020, , 299-322.		0
393	Magenkarzinom. , 0, , 679-691.		0
394	Nierenzellkarzinom. , 2007, , 245-275.		0
395	Nierenzellkarzinom. , 2014, , 347-397.		0
396	The epidemiology of oesophageal cancer in the UK and other European countries. Journal of the Royal Society of Medicine, 1994, 87, 334-7.	2.0	14
397	Cancer clinical outcomes for minority ethnic groups. The British Journal of Cancer Supplement, 1996, 29, S54-60.	0.1	6
398	Prostate cancer survival in Trinidad: Is PSA a prognostic factor?. Canadian Urological Association Journal, 2012, 6, E249-55.	0.6	6
399	Association between TCF7L2 polymorphisms and breast cancer susceptibility: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 9355-61.	1.3	8
402	Estimates of Cancer Incidence in China for 2000 and Projections for 2005. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 243-250.	2.5	285
403	The Epidemiology of Oesophageal Cancer in the UK and other European Countries. Journal of the Royal Society of Medicine, 1994, 87, 334-337.	2.0	32
404	Combination of hyperthermia and intravesical chemotherapy for the treatment of pT1 stage bladder cancer: A retrospectively clinical study. Asia-Pacific Journal of Clinical Oncology, 0, , .	1.1	2
405	Estimativa da incidÃªncia de cÃ¢ncer no Estado de SÃ£o Paulo, Brasil, a partir de dados reais. Cadernos De Saude Publica, 2023, 39, .	1.0	0
406	Maximal Androgen Blockade in Prostatic Cancer. Scandinavian Journal of Urology and Nephrology, 1991, 25, 137-144.	1.4	3
407	RECENT ADVANCES IN THE MEDICAL MANAGEMENT OF PROSTATE CANCER. International Journal of Clinical Practice, 1996, 50, 88-93.	1.7	15